# üö® CONFIDENCE ASSESSMENT & REALITY CHECK
## StarX Therapeutics Analysis - Critical Review
**Generated:** November 2, 2025  
**Status:** Pre-Delivery Confidence Audit

---

## üéØ EXECUTIVE SUMMARY: CONFIDENCE LEVELS

### Overall Project Confidence: **MODERATE (65%)**

**What we're confident about:**
- ‚úÖ DepMap data processing is accurate
- ‚úÖ Multi-target dependency rankings are mathematically sound
- ‚úÖ Statistical methods are appropriate
- ‚úÖ We're being honest about weak signals

**What we're NOT confident about:**
- ‚ö†Ô∏è Experimental validation shows WEAK correlation with DepMap (œÅ = -0.009)
- ‚ö†Ô∏è Only 12.4% overlap between IC50 and DepMap cell lines
- üö® **BRAIN CANCER/STK17A claims do NOT match our data**
- ‚ö†Ô∏è Missing key experimental documents
- ‚ö†Ô∏è Overall dependency signals are weak (mean = -0.09)

---

## üß† BRAIN CANCER / STK17A ISSUE

### What Dr. Taylor's Team Believes:
> "STK17A is promising for brain cancers like glioblastoma"

### What Our Data Actually Shows:

#### Diffuse Glioma (includes Glioblastoma)
- **Rank:** 35 out of 58 cancer types (MIDDLE OF PACK, not top)
- **Combined score:** -0.083 (weak, near overall mean of -0.09)
- **Sample size:** n=17 cell lines (decent)
- **Individual gene dependencies:**
  - STK17A: **-0.080** (VERY WEAK - essentially no dependency)
  - MYLK4: **+0.040** (POSITIVE = not dependent, counterproductive)
  - TBK1: **-0.217** (MODERATE - best target for glioma)
  - CLK4: **-0.076** (VERY WEAK)

#### Experimental Validation for Glioma:
- Only 2 glioma cell lines in IC50 data
- Mean dependency: -0.078 (very weak)
- Validation score: 0.0 (insufficient data)

### üö® CRITICAL FINDING:
**Our analysis does NOT support STK17A as a strong target for brain cancers.**

Only TBK1 shows any meaningful signal in glioma (-0.22), and even that is modest.

### Why the Discrepancy?

**Possible explanations:**

1. **Different Compounds:**
   - Dr. Taylor's team may have tested compounds we don't have data for
   - Missing: Christian's 814H RNAseq + proteomics data
   - Missing: Eduardo's docking/structure files
   - These might show different target engagement profiles

2. **Different Contexts:**
   - Their excitement may be based on specific glioma subtypes not well-represented in DepMap
   - Patient-derived xenografts (PDX) vs. cell lines behave differently
   - In vivo vs. in vitro differences

3. **Combination Effects:**
   - Multi-target inhibition might show synergy not captured by single-gene DepMap
   - The ~160 cell line IC50 data might show combination benefits

4. **Additional Mechanisms:**
   - STK17A might work through mechanisms other than genetic dependency
   - Immune modulation, microenvironment effects not in DepMap
   - Pathway effects beyond direct gene knockout

### ‚ö†Ô∏è RECOMMENDATION:
**Before presenting brain cancer as a top indication, you MUST:**

1. Ask Dr. Taylor: "What specific data makes you excited about STK17A + brain cancer?"
2. Request: Christian's 814H RNAseq data for glioma cell lines
3. Check: Are there PDX or in vivo glioma studies we're missing?
4. Clarify: Which brain cancer subtypes specifically? GBM? Diffuse midline glioma?

**DO NOT claim STK17A is a strong target for brain cancers based on this DepMap analysis alone.**

---

## üìä EXPERIMENTAL VALIDATION RESULTS

### What We Found:
```
IC50 Data:           160 cell lines tested
DepMap Data:         237 cell lines analyzed
Matched:             20 cell lines (12.4% overlap) ‚ö†Ô∏è

Correlation Results:
- Compound 1 (815K) vs DepMap:  œÅ = -0.009, p = 0.97  ‚ùå NO CORRELATION
- Compound 2 (815H) vs DepMap:  œÅ = +0.098, p = 0.68  ‚ùå NOT SIGNIFICANT
```

### What This Means:
- **The experimental IC50 data does NOT validate DepMap predictions**
- Poor overlap (88% of cell lines don't match)
- No meaningful correlation when they do match
- This significantly reduces confidence in DepMap-based rankings

### Why Poor Validation?

**Technical reasons:**
1. Cell line name mismatches (different nomenclature)
2. Different culture conditions affect both dependency and IC50
3. DepMap uses genetic knockout; IC50 uses chemical inhibition (different mechanisms)

**Biological reasons:**
1. Multi-target inhibition ‚â† single-gene knockout
2. Off-target effects in chemical inhibitors
3. Different compounds may hit different combinations of targets

### Impact on Confidence:
- **Reduces confidence in absolute rankings by 30-40%**
- **Increases importance of mutation-stratification (where we saw signals)**
- **Emphasizes need for experimental validation of top candidates**

---

## üìù MISSING DOCUMENTS IMPACT

### What We're Missing:

1. **Christian: 814H RNAseq + New Proteomics** ‚ö†Ô∏è HIGH IMPACT
   - Could show different target engagement profiles
   - Might explain brain cancer excitement
   - **Recommendation:** Get this before final delivery

2. **Eduardo: Docking/Structure Files** üìä MEDIUM IMPACT
   - Would help understand which genes are actually hit by compounds
   - Could explain IC50 vs DepMap discrepancy
   - **Recommendation:** Include if available, not critical for Nov 10

3. **More Glioma-Specific Data** üß† HIGH IMPACT
   - PDX models, in vivo studies
   - Specific GBM subtypes
   - **Recommendation:** Ask Dr. Taylor directly

### What We Have vs. Need:

**Sufficient for Nov 10 Preliminary Report:** ‚úÖ
- DepMap multi-target analysis: Complete
- Expression correlation: Complete
- Mutation context: Complete
- Copy number: Complete
- Literature review: Complete
- Experimental validation: Complete (but weak correlation)

**Missing for Final Confidence:** ‚ö†Ô∏è
- Target engagement confirmation (814H data)
- Brain cancer-specific mechanistic data
- Compound selectivity profiles
- In vivo validation

---

## üéØ CONFIDENCE BY EVIDENCE DIMENSION

### DepMap Dependency Analysis: **HIGH (85%)**
- ‚úÖ Data processing correct
- ‚úÖ Statistical methods sound
- ‚úÖ Rankings are reproducible
- ‚ö†Ô∏è But: Overall signals are weak (mean = -0.09)
- ‚ö†Ô∏è But: Top cancers have small n (1-5 cell lines)

**Confidence in rankings:** High  
**Confidence in absolute dependency magnitudes:** Moderate

---

### Expression Correlation: **MODERATE (70%)**
- ‚úÖ Analysis methodology correct
- ‚úÖ Correlations calculated properly
- ‚ö†Ô∏è But: Correlations are weak to moderate
- ‚ö†Ô∏è But: Expression doesn't strongly predict dependency

**Confidence:** Expression adds signal but isn't a strong predictor alone

---

### Mutation Context / Synthetic Lethality: **MODERATE-HIGH (75%)**
- ‚úÖ Statistical testing appropriate
- ‚úÖ Effect sizes calculated correctly
- ‚úÖ Strongest signals we have (PTEN√óCLK4, p=2.3e-7)
- ‚úÖ Biologically plausible mechanisms
- ‚ö†Ô∏è But: Effect sizes are modest (0.06-0.12)
- ‚ö†Ô∏è But: Small n for mutant cell lines

**Confidence:** This is our strongest evidence dimension  
**Recommendation:** Emphasize mutation-stratification in report

---

### Copy Number Analysis: **MODERATE (65%)**
- ‚úÖ Data processed correctly
- ‚úÖ Amplification frequencies calculated
- ‚ö†Ô∏è But: Amplification ‚â† dependency
- ‚ö†Ô∏è But: Unclear how amplification affects drug sensitivity

**Confidence:** Adds context but not primary evidence

---

### Literature Review: **LOW-MODERATE (60%)**
- ‚úÖ Manual searches documented
- ‚úÖ Top papers identified
- ‚ö†Ô∏è But: Not comprehensive (targeted only)
- ‚ö†Ô∏è But: Many promising cancers have sparse literature
- ‚ö†Ô∏è But: Novel targets = less published validation

**Confidence:** Directionally useful but incomplete

---

### Experimental Validation (IC50 Data): **LOW (40%)**
- üö® Poor correlation with DepMap (œÅ = -0.009)
- üö® Only 12.4% cell line overlap
- üö® Does NOT validate computational predictions
- ‚ö†Ô∏è Unclear which targets are actually hit by 815K/815H

**Confidence:** This is a significant concern  
**Recommendation:** Downweight DepMap, emphasize mutation context

---

## üî¨ WHAT WE CAN CONFIDENTLY CLAIM

### ‚úÖ SAFE TO CLAIM:

1. **Context-Specific Dependencies Exist**
   - "Multi-target inhibition shows dependencies in specific cancer contexts"
   - Supported by DepMap data, even if weak overall

2. **Mutation-Stratified Opportunities**
   - "PTEN-mutant cancers show enhanced CLK4 dependency (p=2.3e-7)"
   - "EGFR-mutant contexts reveal MYLK4 synthetic lethality (p=0.016)"
   - "HRAS-mutant backgrounds show STK17A vulnerability (p=0.040)"
   - These are our strongest, most reproducible signals

3. **Multi-Dimensional Evidence Convergence**
   - "Top candidates show agreement across multiple evidence types"
   - True for top 3-5 cancers where multiple dimensions align

4. **TBK1 and STK17A Show More Consistent Dependencies Than MYLK4**
   - Clear from the data: MYLK4 mean dependency = +0.004 (essentially zero)

5. **Patient Selection Will Be Critical**
   - Given weak overall signals and strong mutation effects

### ‚ö†Ô∏è CLAIM WITH CAVEATS:

1. **"Top 5-10 Cancer Indications Identified"**
   - TRUE: We have rankings
   - CAVEAT: Based primarily on DepMap, which showed weak experimental validation
   - CAVEAT: Top cancers often have n<5 cell lines
   - **Frame as:** "Hypothesis-generating prioritization requiring validation"

2. **"Multi-Omic Evidence Integration"**
   - TRUE: We integrated 6 dimensions
   - CAVEAT: Each dimension has limitations
   - CAVEAT: Experimental validation was weak
   - **Frame as:** "Preliminary multi-dimensional analysis"

3. **"Expression Correlation Validates Dependencies"**
   - PARTIALLY TRUE: Some genes show correlation
   - CAVEAT: Correlations are moderate, not strong
   - **Frame as:** "Expression patterns provide supporting context"

### üö® DO NOT CLAIM:

1. ‚ùå **"These targets are broadly essential"**
   - Data clearly shows context-specific, not essential
   - Mean dependency = -0.09 (very weak)

2. ‚ùå **"Strong synthetic lethality signals"**
   - Effect sizes are modest (0.06-0.12)
   - Claim "statistically significant synthetic lethality" instead

3. ‚ùå **"Experimental data validates DepMap predictions"**
   - Correlation œÅ = -0.009 (no validation)
   - Claim "experimental data available for subset of cancers"

4. ‚ùå **"STK17A is a strong target for brain cancers"** üö®
   - Our data does NOT support this
   - Glioma ranks 35/58, STK17A dependency = -0.08 (very weak)
   - **ASK DR. TAYLOR about this discrepancy**

5. ‚ùå **"High confidence in absolute rankings"**
   - Rankings are relative, not absolute
   - Weak experimental validation
   - Claim "preliminary prioritization" instead

---

## üéØ OVERALL CONFIDENCE ASSESSMENT

### Confidence in Delivering Value to Dr. Taylor: **HIGH (80%)**

**Why high despite concerns:**
1. We're being honest about limitations ‚úÖ
2. Mutation-stratification findings are real ‚úÖ
3. Multi-dimensional framework is sound ‚úÖ
4. We're identifying validation priorities ‚úÖ
5. We're not overclaiming weak signals ‚úÖ

### Confidence in Specific Rankings: **MODERATE (65%)**

**Why moderate:**
1. DepMap signals are weak overall
2. Experimental validation didn't correlate
3. Top cancers have small sample sizes
4. Rankings are relative, not absolute

### Confidence in Mutation-Stratified Opportunities: **HIGH (75%)**

**Why high:**
1. Statistically significant findings
2. Biologically plausible mechanisms
3. Multiple independent signals (PTEN, EGFR, HRAS)
4. This is where real effect sizes appear

### Confidence in Need for Experimental Validation: **VERY HIGH (95%)**

**Why very high:**
1. Weak DepMap signals ‚Üí must validate
2. Poor IC50 correlation ‚Üí need better data
3. Brain cancer discrepancy ‚Üí must resolve
4. This is a preliminary analysis ‚Üí validation planned

---

## üö® RED FLAGS TO ADDRESS WITH DR. TAYLOR

### Before Nov 10 Delivery:

1. **Brain Cancer / STK17A Discrepancy** üö® CRITICAL
   - Ask: "What specific data makes you excited about STK17A + brain cancers?"
   - Ask: "Do you have in vivo glioma data we're missing?"
   - Ask: "Which brain cancer subtypes specifically?"

2. **Experimental Validation Concern** ‚ö†Ô∏è IMPORTANT
   - Inform: "IC50 data shows weak correlation with DepMap predictions (œÅ = -0.009)"
   - Ask: "Is this expected given multi-target vs. single-gene effects?"
   - Ask: "Should we downweight DepMap in favor of mutation context?"

3. **Missing 814H Data** ‚ö†Ô∏è IMPORTANT
   - Ask: "Can Christian provide the 814H RNAseq data before Nov 10?"
   - Explain: "This could help explain DepMap vs. IC50 discrepancy"

4. **Overall Signal Weakness** ‚ö†Ô∏è MODERATE
   - Inform: "Mean dependency = -0.09, indicating context-specific rather than essential"
   - Ask: "Does this match your in-house findings?"
   - Frame: "This suggests biomarker-driven development strategy"

---

## üìã RECOMMENDATIONS FOR NOV 10 REPORT

### Framing Strategy:

**EMPHASIZE:**
1. ‚úÖ Mutation-stratified opportunities (strongest signals)
2. ‚úÖ Context-specific dependencies (true and important)
3. ‚úÖ Multi-dimensional evidence framework (rigorous approach)
4. ‚úÖ Validation priorities (next steps clear)

**DE-EMPHASIZE:**
1. ‚ö†Ô∏è Absolute dependency magnitudes (weak)
2. ‚ö†Ô∏è Experimental validation strength (poor correlation)
3. ‚ö†Ô∏è MYLK4 as priority target (weakest signal)

**CAVEAT CLEARLY:**
1. ‚ö†Ô∏è Small sample sizes for top cancers
2. ‚ö†Ô∏è Preliminary findings requiring validation
3. ‚ö†Ô∏è Limited experimental validation
4. ‚ö†Ô∏è Rankings are hypothesis-generating

**DO NOT INCLUDE:**
1. ‚ùå Brain cancer as top indication (unless Dr. Taylor explains discrepancy)
2. ‚ùå Claims of "strong" dependencies or synthetic lethality
3. ‚ùå Experimental validation of DepMap predictions

---

## üéØ FINAL CONFIDENCE STATEMENT

### Bottom Line:

**This analysis provides scientifically rigorous, honest, hypothesis-generating prioritization of cancer indications based on multi-dimensional computational evidence.**

**Strengths:**
- Rigorous computational analysis ‚úÖ
- Honest about limitations ‚úÖ
- Clear mutation-stratification opportunities ‚úÖ
- Identifies validation priorities ‚úÖ

**Limitations:**
- Weak overall dependency signals ‚ö†Ô∏è
- Poor experimental validation correlation ‚ö†Ô∏è
- Small sample sizes for top cancers ‚ö†Ô∏è
- Missing key experimental context (814H) ‚ö†Ô∏è

**Confidence in Value Delivered:** **HIGH (80%)**

**Confidence in Specific Claims:** **MODERATE (65%)**

**Confidence in Approach:** **VERY HIGH (90%)**

---

## ‚úÖ ACTION ITEMS BEFORE DELIVERY

### CRITICAL (Must Do):

1. ‚ö†Ô∏è **Call or email Dr. Taylor about brain cancer / STK17A**
   - "Our DepMap analysis shows glioma ranking 35/58 with STK17A dependency of -0.08 (very weak). Can you help me understand what makes you excited about STK17A for brain cancers? Do you have additional data we should integrate?"

2. ‚ö†Ô∏è **Request Christian's 814H RNAseq data**
   - This could resolve experimental validation concerns

3. ‚ö†Ô∏è **Frame report appropriately**
   - Preliminary / hypothesis-generating
   - Emphasize mutation stratification
   - Clear validation needed

### IMPORTANT (Should Do):

4. ‚ö†Ô∏è **Adjust scoring weights in PROMPT 4**
   - Consider reducing DepMap weight from 30% given poor validation
   - Consider increasing mutation context weight from 20%

5. ‚ö†Ô∏è **Add experimental validation caveats throughout report**
   - Note weak IC50 correlation
   - Emphasize need for validation

6. ‚ö†Ô∏è **Check if Eduardo's docking data available**
   - Could help understand target selectivity

---

## üìä CONFIDENCE SCORE SUMMARY

| Component | Confidence | Rationale |
|-----------|------------|-----------|
| **Data Processing** | 95% | ‚úÖ Accurate and reproducible |
| **DepMap Analysis** | 85% | ‚úÖ Sound methods, ‚ö†Ô∏è weak signals |
| **Expression Analysis** | 70% | ‚úÖ Complete, ‚ö†Ô∏è moderate correlations |
| **Mutation Context** | 75% | ‚úÖ Strongest signals, ‚ö†Ô∏è modest effect sizes |
| **Copy Number** | 65% | ‚úÖ Processed correctly, ‚ö†Ô∏è unclear impact |
| **Literature Review** | 60% | ‚ö†Ô∏è Targeted only, not comprehensive |
| **Experimental Validation** | 40% | üö® Poor DepMap correlation |
| **Brain Cancer Claims** | 20% | üö® Data does NOT support excitement |
| **Overall Rankings** | 65% | ‚ö†Ô∏è Hypothesis-generating, need validation |
| **Mutation Stratification** | 75% | ‚úÖ Real signals, actionable |
| **Value to Client** | 80% | ‚úÖ Honest, rigorous, actionable |

### **OVERALL PROJECT CONFIDENCE: 65% ¬± 10%**

---

**Date:** November 2, 2025  
**Analyst:** Parker Case  
**Status:** Ready for Dr. Taylor discussion before finalizing Nov 10 report

**Next Step:** Contact Dr. Taylor to discuss brain cancer / STK17A discrepancy and request missing data.
